The Role of Radionuclide Imaging in the Surgical Management of Primary Hyperparathyroidism

Elif Hindié¹, Paolo Zanotti-Fregonara¹, Antoine Tabarin², Domenico Rubello³, Isabelle Morelec⁴, Tristan Wagner⁵, Jean-François Henry⁶, and David Taïeb⁷

¹Department of Nuclear Medicine, Haut-Lévêque Hospital, CHU de Bordeaux, CNRS-UMR 5287, Translational and Advanced Imaging Laboratory (TRAIL), University of Bordeaux, Bordeaux, France; ²Department of Endocrinology, CHU de Bordeaux, University of Bordeaux, Bordeaux, France; ³Department of Nuclear Medicine, Santa Maria della Misericordia Hospital, Rovigo, Italy; ⁴Department of Nuclear Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France; ⁵Department of Endocrine Surgery, CHU de Bordeaux, University of Bordeaux, Bordeaux, France; ⁶Department of Endocrine Surgery, La Timone Hospital, Aix-Marseille University, Marseille, France; and ⁷Department of Nuclear Medicine, La Timone Hospital, CERIMED, Aix-Marseille University, Marseille, France

Learning Objectives: On successful completion of this activity, participants should be able should be able to describe (1) the role of parathyroid scintigraphy before bilateral cervicotomy or minimally invasive surgery for primary hyperparathyroidism; (2) the performance of different imaging protocols to detect multiglandular disease; (3) the appropriate imaging strategy before reoperation for persistent or recurrent hyperparathyroidism; and (4) the potential use of novel PET tracers.

Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest.

CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through May 2018.

Primary hyperparathyroidism is a frequent and potentially debilitating endocrine disorder for which surgery is the only curative treatment. The modalities of parathyroid surgery have changed over the last 2 decades, as conventional bilateral neck exploration is no longer the only surgical approach. Parathyroid scintigraphy plays a major role in defining the surgical strategy, given its ability to orient a targeted (focused) parathyroidectomy and to recognize ectopic locations or multiglandular disease. This review, which represents a collaborative effort between nuclear physicians, endocrinologists, and endocrine surgeons, emphasizes the importance of performing imaging before any surgery for primary hyperparathyroidism, even in the case of conventional bilateral neck exploration. We discuss the advantages and drawbacks of targeted parathyroidectomy and the performance of various scintigraphic protocols to guide limited surgery. We also discuss the optimal strategy to localize the offending gland before reoperation for persistent or recurrent hyperparathyroidism. Finally, we describe the potential applications of novel PET tracers, with special emphasis on ¹⁸F-fluorocholine.

Key Words: hyperparathyroidism; MIBI; dual-tracer; parathyroid subtraction imaging; SPECT/CT; PET/CT; ¹⁸F-fluorocholine; ¹¹C-methionine

J Nucl Med 2015; 56:737–744
DOI: 10.2967/jnumed.115.156018

Primary hyperparathyroidism (PHPT) is the third most common endocrine disorder after diabetes and hyperthyroidism (1). The prevalence in women over the age of 50 y is about 2% (2). The condition is often diagnosed in asymptomatic subjects during a routine serum calcium measurement (1,3). PHPT is classically associated with an elevated level of total serum calcium (after adjustment for albumin concentration) and of serum parathyroid hormone (PTH). However, in some patients PTH levels may be normal but inappropriate to hypercalcemia. Patients with vitamin D insufficiency may have higher PTH levels, and thus 25-hydroxyvitamin D should be measured. One important differential diagnosis is familial hypocalciuric hypercalcemia, because surgery is not warranted for this condition, which is due to heterozygous calcium-sensing receptor gene mutations and is associated with a low urinary calcium level.

The clinical signs and symptoms that are often associated with PHPT involve the skeleton (osteoporotic fractures, pain, bone lesions, chondrocalcinosis), the kidneys (nephrolithiasis, nephrocalcinosis, impaired renal function), and, more rarely now, the digestive tract (peptic ulcers, constipation, pancreatitis) and the cardiovascular system (hypertension) (1–4). PHPT may also cause neuropsychiatric symptoms, cognitive impairments, and decreased quality of life. Hypercalcemic crisis is rare but is a life-threatening medical emergency.

Patients with asymptomatic PHPT may remain stable over many years or show progression. After 15 y of prospective follow-up, about a third of subjects develop additional signs of the disease (e.g., kidney stones, worsening hypercalcemia, reduced bone mineral density, or fragility fractures) (3).

Surgery is the only curative treatment for PHPT. According to recent recommendations (4), surgery is indicated in any patient...
USEFULNESS OF PREOPERATIVE IMAGING BEFORE CONVENTIONAL BILATERAL SURGERY

Without imaging, bilateral cervical exploration is curative in 92%–95% of patients who undergo surgery for PHPT, as shown by older studies done before modern imaging was available (5). Indeed, an experienced surgeon can identify most pathologic glands (9,23–25).

However, preoperative imaging allows selection of patients eligible for targeted surgery and identification of ectopic glands. The incidence of ectopic glands is estimated at 6%–16% (24). Most ectopic glands present minor ectopia (e.g., in thyrohyoid ligaments, in the tracheoesophageal groove, or partially embedded in the thyroid) and are easily located by an experienced surgeon. However, some parathyroid glands present major ectopia, which may lead to surgical failure, even for experienced surgeons, and can be a source of medical litigation. For example, 1%–2% of subjects have ectopic glands that require thoracic surgery instead of cervical surgery (23,24).

In agreement with recommendations (16), we think that preoperative imaging should always be performed. Good imaging should be effective, provide morphologic and functional information, be noninvasive, and not be too expensive. These conditions can be fulfilled by combining cervical ultrasound and scintigraphy.

Positive Parathyroid Scans

Even in the case of classic bilateral cervicotomy, preoperative imaging has several benefits. It reduces the extent of anatomic dissection or unnecessary thyroid resections and morbidity, especially with regard to recurrent laryngeal nerve palsy, hypoparathyroidism, and hematomas. It reduces operation time; the surgeon starts by exploring the suspected site and the tumor can be sent for pathologic examination while the surgeon proceeds with inspection of the remaining parathyroid glands (26). It detects ectopic cervical glands without the need for extensive dissections. It detects thoracic glands that are not accessible through the neck (26).

In a retrospective series of 202 resected ectopic glands (major and minor ectopias), preoperative scintigraphy had a sensitivity of 89% and a positive predictive value of 90%. Among 59 patients who underwent both scintigraphy and ultrasound, scintigraphy was superior to ultrasound in 28 patients and inferior in 3 (27). Ultrasound detection is hampered in cases of a retrotracheal, retroesophageal, or intrathoracic parathyroid gland.

Ectopias can be acquired or congenital. Tumors from superior parathyroid glands (also named P4) may prolapse along the tracheoesophageal groove into the lower neck or upper mediastinum and can be found in a para- or retroesophageal position. By contrast, ectopias of the lower parathyroids (P3) are often congenital and are due to an abnormal migration of the glands. They may be near the carotid and jugular vessels in the neck or inside the thymus in the anterior mediastinum. More rarely, pathologic glands can be associated with the vagal nerve within the carotid sheath or in the aortopulmonary window. Parathyroid glands completely buried in the thyroid parenchyma may be derived from P3 or P4 or may be supernumerary.

Suspecting a MGD on preoperative imaging may help the surgeon plan the surgical approach.
Finally, although thyroid nodules may be a cause of false-positives on parathyroid scintigraphy, it should not be forgotten that a $^{99m}$Tc-sestamibi-positive, $^{123}$I-iodine-negative thyroid nodule carries a risk of malignancy (28) and may justify fine-needle biopsy before parathyroid surgery.

**Negative Parathyroid Scans**

In principle, imaging results should not influence the surgical decision (12,29). However, some recent studies (30–32), although not all (33), reported that surgical failure rate is higher when preoperative imaging findings are negative.

According to a multicenter study, patients with negative ultrasound and scintigraphy results had smaller parathyroid lesions and a higher proportion of hyperplasia (22%). Moreover, cervicotomy involved a higher number of extended surgical procedures, such as thyroidectomy and thymectomy. Finally, PHPT was still present in 18% of subjects after surgery (30). Even in a center with great experience, the Mayo Clinic, the surgical failure rate in scintigraphy-negative patients can be as high as 10% despite the use of an intraoperative PTH assay (31).

Thus, negative imaging results are also informative and indicate that an experienced multidisciplinary team, including a surgeon, an endocrinologist, and imaging specialists, should be entrusted with the case.

**ADVANTAGES AND DISADVANTAGES OF TARGETED SURGERY**

Targeted parathyroidectomy has several advantages: a lower rate of complications, such as hypoparathyroidism, nerve injury, or unaesthetic scars; a shorter operation time; and a higher possibility of outpatient surgery and local anesthesia. The option of targeted surgery should, however, be entertained only if the rate of failure (e.g., unrecognized MGD) is acceptably low. A Swedish randomized study (34) showed an advantage for unilateral surgery, in terms of operative time and incidence of transient hypocalcemia, whereas the rate of failure (persistent or recurrent hyperparathyroidism) was not significantly higher (8.5% for unilateral surgery vs. 4.5% for bilateral surgery). However, a potential bias to these comparisons is that patients randomized for bilateral surgery did not undergo scintigraphy (26).

To reduce the risk of failure, several institutions associate targeted surgery with intraoperative PTH monitoring (7). PTH has a short half-life in plasma (2–4 min). According to the widely used Miami criterion (35), a 50% decrease in PTH levels 10 min after removal of the putative lesion suggests a curative surgery. However, the procedure may sometimes yield inaccurate results, as when PTH concentrations decrease even in the presence of a second smaller lesion (36,37). The prevalence of MGD, estimated on the basis of intraoperative PTH monitoring, is about 5% (35), much lower than the conventional rate of 15%–20% (5,38). Intraoperative PTH monitoring may also wrongly lead to delayed surgery, because of delayed decay of PTH in cases of excessive mobilization of the adenoma before its removal or slow elimination kinetics in some patients.

Although recommended when performing targeted parathyroidectomy (7), rapid PTH assays are not available to most surgeons worldwide (7). Moreover, PTH monitoring prolongs operation time and limits the feasibility of local anesthesia. As an alternative to intraoperative PTH, some surgeons recommend inspection of the ipsilateral gland (39). In the case of double-adenomas, however, bilateral distribution is expected, not only because of probability (two thirds of the cases) but also because they often originate from the two superior glands (40).

Another point to consider is that targeted surgery may require conversion to bilateral surgery in about 20% of cases (41,42). Conversion is often due to imaging failure: wrong localization or MGD missed by imaging and identified by inspection of the ipsilateral gland or intraoperative PTH monitoring (41).

In summary, as stated in the SNMMI and EANM guidelines, a good preoperative imaging study can play a major role in the selection of candidates for targeted surgery (17,18).

**PERFORMANCE OF DIFFERENT SCINTIGRAPHIC PROTOCOLS TO GUIDE TARGETED SURGERY**

A valuable presurgical imaging technique should be able to identify MGD, limit the rate of false-positives (e.g., thyroid nodules), and detect small lesions. Small parathyroid lesions are increasingly frequent because of earlier detection of PHPT. In the study of Almquist et al., the median weight of adenomas decreased from 750 mg for women who underwent surgery between 1990 and 1995 to 520 mg for those who underwent surgery between 2000 and 2007 (43).

Ultrasound is not accurate enough to be used alone for targeted surgery. It has a low sensitivity for MGD and ectopic lesions. In the study by Haber et al. (44), ultrasound recognized only 17% of MGD cases (1/6) and 25% of ectopic glands (2/8).

Although a metaanalysis showed that scintigraphy is superior to ultrasound, its sensitivity decreases in the case of MGD (88.44% for single adenoma, 44.46% for hyperplasia, and 29.95% for dual adenoma). Moreover, sensitivity varies greatly among different studies (15). A description of the single-tracer dual-phase and dual-tracer subtraction parathyroid scintigraphy protocols can be found in the EANM and SNMMI guidelines (17,18). The techniques are also summarized in Supplemental Table 1 (available at http://jnm.snmjournals.org).

Dual-phase $^{99m}$Tc-sestamibi scintigraphy, generally using a parallel collimator and imaging at 15 min and 2–3 h, cannot detect MGD most of the time (45,46). Indeed, many hyperplastic parathyroid lesions do not significantly retain the tracer at a late time. Among the 11 MGD patients of the study by Martin et al., double-phase scintigraphy wrongly suggested a single adenoma in 9 cases and was negative in the remaining 2 cases (46). In addition, this technique has a high rate of false-positives because of the absence of a thyroid-specific tracer. The sensitivity of $^{99m}$Tc-sestamibi single-tracer scintigraphy can be improved by adding pinhole acquisitions and SPECT/CT (47). The percentage of detected MGD cases remains, however, limited. Therefore, we think that single-tracer dual-phase scintigraphy cannot reliably guide targeted parathyroid surgery.

For the same reason, the use of intraoperative $\gamma$ probes to opt for targeted surgery has severe limits. Murphy and Norman argued that any excised tissue containing more than 20% of background activity, in a patient with positive $^{99m}$Tc-sestamibi results, is likely to be a solitary adenoma (48). However, because MGD is rarely seen on late scintigraphic images (17,46), this approach was recently abandoned by the very team who first proposed it (49).

**Importance of Simultaneous Dual-Tracer Imaging**

Hindié et al. proposed a $^{99m}$Tc-sestamibi/$^{123}$I subtraction protocol based on the simultaneous acquisition of the two tracers (instead of a sequential acquisition) (26). Dual-isotope acquisition...
artifact. Pinhole images offer better resolution. After subtraction (F), 2 foci are clearly seen on right side, one corresponding to $^{123}$I-cold thyroid nodule (arrowhead) and the other, at inferior pole, corresponding to parathyroid lesion (arrow).

If not available, $^{123}$I can be replaced by $^{99m}$Tc-pertechnetate; its sensitivity for MGD detection is about 60% ($^{56,57}$). In fact, the use of $^{99m}$Tc-pertechnetate precludes the acquisition of a simultaneous image and the subtraction image may thus suffer from motion artifacts. Moreover, dual-isotope SPECT/CT acquisition would not be possible.

Dual-tracer imaging should be performed at least 3 wk after radiologic examinations involving administration of $^{123}$I-iodine contrast medium. Also, thyroid hormone replacement therapy should be withheld for 2 wk before imaging. This is necessary even in cases of previous thyroidectomy, as $^{123}$I would allow the correct identification of residual thyroid tissue, which can be mistaken for an enlarged parathyroid on $^{99m}$Tc-sestamibi single-tracer scintigraphy or neck ultrasound (Fig. 3).

**The Role of Dual-Isotope SPECT/CT**

Tomographic imaging (SPECT or SPECT/CT) of the parathyroids is less sensitive than, and therefore cannot replace, pinhole imaging, especially because the shoulders are in the field of view ($^{58}$). In a prospective study by Neumann et al., subtraction SPECT/CT had an overall sensitivity of 70% ($^{59}$). Subtraction is more complex with dual-isotope tomographic images than with pinhole planar images. In our clinical practice, we prefer to visually compare the 3 tomographic projections of $^{99m}$Tc-sestamibi and $^{123}$I images, without subtraction. We perform subtraction only on pinhole images (Fig. 2).

However, complementary SPECT/CT provides useful information ($^{59,60}$), such as the correct anatomic localization of a lesion.


**Figure 3.** Patient with PHPT and previous history of subtotal thyroidectomy for Graves disease. Neck ultrasound suggested parathyroid lesion on lower right side. Simultaneous dual-tracer acquisition of 99mTc-sestamibi and 123I images was performed after thyroid hormone replacement therapy had been withheld for 2 wk. In large-field-of-view parallel-hole collimator images of 99mTc-sestamibi (A), 123I (B), and subtraction (C), suggestive lesion on ultrasound seems to correspond to thyroid remnant, with no visible neck foci on subtraction image (also confirmed in pinhole view). Intense focus of 99mTc-sestamibi uptake is seen in thorax. Axial 99mTc-sestamibi SPECT/CT fusion image (D) and corresponding CT view (E) identify 9 × 9 × 15 mm mediastinal lesion in front of ascending aorta. At surgery, it corresponded to 537-mg parathyroid adenoma.

Parathyroid Imaging with Novel PET Tracers

11C-methionine seems to be a sensitive tracer for imaging patients before reoperation (65,68,69). In a study by Schalin-Jantti et al., the sensitivity of 11C-methionine PET was comparable to that of subtraction scintigraphy (65% with one false-positive vs. 59% with no false-positive) (68). In another series that investigated patients with previous neck surgery and negative single-tracer 99mTc-sestamibi SPECT/CT results, 11C-methionine PET/CT was positive in 6 of 15 cases (40%) (69). However, because of restricted availability and cost, there probably is little role for routine use of 11C-methionine in PHPT patients undergoing a first operation. Moreover, preliminary data suggest that the sensitivity of 11C-methionine in MGD patients is limited (70).

18F-FDG PET has poor sensitivity in unselected PHPT patients. However, it can offer complementary information to 99mTc-sestamibi in patients with parathyroid carcinoma.

Recently, several short series of patients imaged with choline tracers have been published. Orevi et al. compared 11C-choline with 99mTc-sestamibi/99mTc-pertechnetate scintigraphy in 40 patients experienced teams (63). Accurate preoperative localization is therefore essential.

First-line imaging should include both scintigraphy and neck ultrasound. Concordant localization by two modalities is required. In the case of a cervical image of uncertain origin, ultrasound-guided fine-needle aspiration for PTH assay may be performed (16). Contrast-enhanced CT (or MR imaging) is used to confirm a thoracic gland found by scintigraphy or if neck ultrasound and scintigraphy results are negative or inconclusive. A 4D CT scanner seems to offer good sensitivity, at the price of a high number of false-positives (e.g., exophytic thyroid nodules or lymph nodes) (64). When available, PET/CT with 11C-methionine, 11C-choline, or 18F-fluorocholine can also be proposed. Finally, when imaging results are inconclusive, invasive procedures such as selective venous sampling with PTH measurements may be warranted (16), but the yield is highly dependent on the operator’s expertise (65,66). If the pathologic gland cannot be identified beforehand, the rationale for reoperation is questionable and medical treatment (e.g., with calcimimetics) should be discussed.

Thus, 99mTc-sestamibi scintigraphy plays a major role in surgical decision making. Unfortunately, several studies have reported a low sensitivity. In a series of 19 reoperated patients (18 glands resected in 17 patients and 2 patients with negative surgery), the sensitivity of 99mTc-sestamibi scintigraphy (double-phase planar imaging plus SPECT) was 33% (6/18) and the positive predictive value 67% (69). This translated into a low cure rate (11/19 patients) (67). Again, the sensitivity of dual-tracer scintigraphy in patients with persistent hyperparathyroidism seems to be quite a bit higher than that of single-tracer scintigraphy, as shown in a prospective study by Schalin-Jantti et al. comparing different techniques for the localization of parathyroid glands (68). Reoperation, after taking into account the results of the various techniques, cured 18 of 21 patients (86%) and led to the resection of 19 pathologic glands. The sensitivity of subtraction scintigraphy (planar imaging with a parallel-hole collimator only) was 59% and that of single-tracer 99mTc-sestamibi (double-phase plus SPECT/CT) was 19% (P < 0.01). There were no false-positives with either technique. Selective venous sampling with PTH assay yielded a sensitivity of only 40% with 9 false-positives, including the 3 patients in whom reoperation was unfruitful (68).

**Imaging Strategy Before Reoperation for Persistent or Recurrent Hyperparathyroidism**

The decision to operate again should be made carefully, as the complication rate is higher than for a first surgery, even for
bi/123I subtraction imaging (Table 2 of Michaud et al. showed higher sensitivity than 99mTc-sestamibi scintigraphy to-background and lesion-to-thyroid contrast). 18F-fluorocholine images were better defined at 60 min than at 5 min (better lesion-peroperative PHPT or patients undergoing their first operation with clarifying the role of choline imaging in specific settings (e.g., reoperative).

Thyroid lesions were more clearly seen on 18F-fluorocholine in 2 patients with false-positive findings on 11C-choline (71). In view of the wider availability of 18F-fluorocholine, recent findings with this tracer are of particular interest. Lezaic et al. compared 18F-fluorocholine (with imaging at 5 and 60 min) to 99mTc-sestamibi (double-phase imaging plus early SPECT/CT and 99mTc-pertechnetate thyroid scanning). In 24 patients undergoing surgery for PHPT, surgery identified 39 lesions (17 patients had a solitary adenoma and 7 had MGD). 18F-fluorocholine images were better defined at 60 min than at 5 min (better lesion-to-background and lesion-to-thyroid contrast). 18F-fluorocholine showed higher sensitivity than 99mTc-sestamibi scintigraphy (92% vs. 64%) (72). Although the findings from this study are appealing, the sensitivity of 99mTc-sestamibi was lower than would be expected in previously unoperated PHPT patients (51).

In another series, 18F-fluorocholine with both dynamic and static acquisitions was used in patients with discordant findings at ultrasound and subtraction scintigraphy. In the 8 patients with PHPT who underwent surgery, 18F-fluorocholine offered good sensitivity, although its results mostly confirmed the findings of 99mTc-sestamibi/123I subtraction imaging (Table 2 of Michaud et al. (73)). Parathyroid lesions were more clearly seen on 18F-fluorocholine in 2 patients and on 99mTc-sestamibi/123I subtraction in 1 patient. In 1 patient, 18F-fluorocholine identified a contralateral lesion not seen on 99mTc-sestamibi/123I subtraction, which turned out, however, to be a false-positive.

Larger prospective studies are needed to compare 18F-fluorocholine PET/CT with state-of-the-art conventional scintigraphy to clarify the role of choline imaging in specific settings (e.g., reoperative PHPT or patients undergoing their first operation with inconclusive imaging). A potential advantage of 18F-fluorocholine imaging is the higher resolution associated with PET technology (Fig. 4) and the shorter imaging time. Potential drawbacks are the higher cost and the absence of a specific thyroid tracer, with risk of false-positive results from thyroid nodules and inflammatory lymph nodes. Administration of intravenous contrast medium during choline PET/CT imaging may further improve results, especially in cases of recurrent disease.

CONCLUSION

The long-term cure rate of parathyroid surgery depends on the ability to resect hyperfunctioning parathyroid tumors and to identify MGD and ectopic glands. Preoperative detection of pathologic glands would avoid inappropriate surgery and reduce the rate of surgical conversion or failure. Subtraction scintigraphy after simultaneous acquisition of 99mTc-sestamibi and 123I images provides better sensitivity than double-phase 99mTc-sestamibi scanning. Imaging with a pinhole collimator optimizes resolution. Complementary SPECT/CT images are of great value for anatomic localization and should be obtained routinely before reoperation to identify ectopic glands. Choline PET tracers may open new venues for radionuclide imaging of parathyroid glands.

REFERENCES


The Role of Radionuclide Imaging in the Surgical Management of Primary Hyperparathyroidism

Elif Hindié, Paolo Zanotti-Fregonara, Antoine Tabarin, Domenico Rubello, Isabelle Morelec, Tristan Wagner, Jean-François Henry and David Taïeb

Published online: April 9, 2015.
Doi: 10.2967/jnumed.115.156018

This article and updated information are available at:
http://jnm.snmjournals.org/content/56/5/737

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml